Aptadel Therapeutics is a preclinical spin-off co-founded by Dr. Óscar Martínez-Tirado of IDIBELL and the Alba Pérez Foundation in late 2020. It is developing a new targeted cancer therapy platform using RNA Aptamer technology.
In early 2021, the company completed a €1.7 million round of investment, which will allow it to validate its studies with Ewing sarcoma, its main line of research.
In this interview, Gisela Lorente, Chief Scientific Officer (CSO), explains the need for a good team, the strategic decisions Aptadel Therapeutics has made, and the importance of being motivated and believing in it. She also reveals that you have to keep moving forward and learning from your decisions, even when they turn out to be mistakes.